

Editorial

2019 Eberhard F. Mammen Award Announcements: Part II—Young Investigator Awards

Emmanuel J. Favaloro, PhD, FFSc (RCPA)¹

¹ Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), Sydney Centres for Thrombosis and Haemostasis, Westmead Hospital, Westmead, New South Wales, Australia

Semin Thromb Hemost 2020;46:105–113.

Welcome to another of our Eberhard F. Mammen award announcements. As noted many times previously, Thieme, the publisher of *Seminars in Thrombosis & Hemostasis* (STH), has created the “Eberhard F. Mammen Excellence in Thrombosis and Hemostasis Awards” in honor of Eberhard Mammen (► **Fig. 1**), and in recognition of his contribution to this field and to the journal that he both founded and steered for over 3 decades (► **Table 1**). These awards began in 2009, under two categories; the current award details and conditions are as follows:

- Most popular article awards: Awarded to the authors of the most popular articles published in STH. The awards are determined by the Editor in Chief on the basis of user statistics from Thieme e-Journals from the preceding 2 years. Prefaces, Errata, Letters to the Editor, and Editorials, and previous award-winning articles, are excluded from further consideration of these awards, which currently comprise two categories—one for “Open Access” articles, and another for “General Category.” There are two major cash prizes of US\$1,000 for each category. In addition, winners of the “General Category” awards are granted “open access” status for these articles thereafter.
- Young Investigator Awards: Best presentation or meeting abstract by a young investigator—as presented or delivered to an international or large regional meeting on a topic related to the fields of thrombosis and hemostasis, and whose subject matter is determined to be in the spirit of Dr Mammen, up to six cash prizes of US\$1,000 in any year. There are some additional considerations and conditions for the award, and awardees are expected to prepare a review or other paper related to the topic of their presentation (or as otherwise agreed) for publication

in STH. In general, previous award winners are excluded from a second award to enable more individuals to be recognized. After nominations are received, the awardees are selected by a vote of the senior editors of STH. Any potential conflicts of interests are managed by first identifying these, and then excluding those with potential conflicts from voting.

Further details of the awards and the award winners are posted online (<<https://www.thieme-connect.com/products/ejournals/journal/10.1055/s-00000077>>), and previous award winner announcements are also available in print (see ► **Table 1** for a listing of relevant editorials published in this journal as related to the initiation of the Eberhard F. Mammen awards, as well as previous award announcements; these publications are also available for free download from the journal Web site: <<https://www.thieme-connect.com/products/ejournals/journal/10.1055/s-00000077>>).

The winners of the 2019 Eberhard F. Mammen awards for the most popular articles from STH for the period of 2017 to 2018 inclusive were announced in an earlier issue of the journal.¹ It is therefore with great pleasure that we would like to announce the winners of the latest round of Young Investigator Awards.

As mentioned above, the Young Investigator Awards represent winners of the best presentation or meeting abstract by a young investigator—as presented or delivered to an international or large regional meeting on a topic related to the fields of thrombosis and hemostasis, and whose subject matter is determined to be in the spirit of Dr Mammen. There are additional considerations given that the nominees' presentations are not always seen by all of the possible award nominators, being drawn from the editorial

Address for correspondence
Emmanuel J. Favaloro, PhD, FFSc (RCPA), Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), Sydney Centres for Thrombosis and Haemostasis, Westmead Hospital, Westmead, NSW 2145, Australia
(e-mail: emmanuel.favaloro@health.nsw.gov.au).

Issue Theme The Complexity of Trauma-Induced Coagulopathy; Guest Editors: Hau C. Kwaan, MD, FRCP, Hunter B. Moore, MD, PhD, Robert L. Medcalf, PhD, and Mark Walsh, MD.

Copyright © 2020 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.
Tel: +1(212) 760-0888.

DOI <https://doi.org/10.1055/s-0040-1702201>.
ISSN 0094-6176.



Fig. 1 Eberhard F. Mammen (1930–2008).

team of the journal. The latest winners are identified below and also in ►Table 2, with a running list of previous awardees, and the resulting publications in the journal, given in ►Table 3. The latest awardees are derived from a variety of meetings, but primarily the latest meeting of the International Society on Thrombosis and Haemostasis (ISTH) held in Melbourne, Australia, in July 2019 (ISTH 2019).

As sometimes occurs with these awards, the current crop of winners reflects a variety of “Young Investigators” at various stages of their careers. While some awardees are just starting out on their journey in science or medicine, others are better established in their careers and crossing over into the next phase of their calling where they will soon no longer be called “young” investigators.

Dr Elisa Danese (►Fig. 2) was born in Verona (Italy) and currently serves as Assistant Professor of Clinical Biochemistry at the University of Verona. She has a degree in Pharmaceutical Chemistry, a Specialization in Clinical Biochemistry and a PhD degree in Medical, Clinical, and Experimental Science. She has published over 100 articles in peer-reviewed journals and has participated in more than 50 national and international congresses. She is also a current associate editor of the international journal “Annals of Translational Medicine.” She was nominated for a talk she gave as a State-of-the-Art presentation at ISTH2019.

Soracha Ward (►Fig. 3) is a PhD candidate in the Irish Centre for Vascular Biology. She topped in her graduation with a first-class honors BSc in Biomedical Science from University College Cork in 2014. Thereafter, she joined the Haemostasis Research Group in Trinity College, Dublin where her research focuses primarily on the role of von Willebrand factor (VWF)

glycosylation in modulating circulatory half-life. As published in the journal *Blood*, her work led to the identification of a novel VWF clearance receptor, macrophage galactose lectin.² Soracha has presented her research at both international and national meetings, for which she has won numerous awards. In particular, she won an ASH abstract achievement award and was recognized as “Best of ASH” at the 60th annual meeting of the American Society of Haematology. Indeed, that was the basis of her nomination for the 2019 Eberhard F. Mammen YIA.

Jonathan Douxfils (►Fig. 4) obtained his PhD in biomedical and pharmaceutical sciences in 2015. In 2018, he gained an academic position at the University. His research focuses on the establishment of guidelines for the laboratory measurement of direct oral anticoagulants in the routine setting. So far, such recommendations have been used by several expert societies involved in the field of thrombosis and hemostasis. He also exercises his expertise as a pharmacovigilance expert at the European Medicine Agency, is co-chairman of the ISTH SSC “Control of Anticoagulation” and a co-founder and CEO of QUALblood, a Contract Research Organization aiming to provide industries, hospitals, and universities with analytical services for blood investigations and hemocompatibility testing. Passionate about clinical and laboratory research, he is involved in several current projects aiming to improve the safety and effectiveness of therapeutic agents to promote public health. Dr Douxfils has the enviable position of actually getting two nominations for the 2019 YIA (►Table 2).

Erik Klok (►Fig. 5) has been involved in studies about the management of venous thromboembolism (VTE) since 2007, focused on answering several questions about optimization of diagnostic management of VTE and implementation of findings from diagnostic studies into clinical practice. Such questions are especially relevant for particular patient groups or clinical circumstances, including pregnant women, the elderly, and patients with cancer. The combination of being a clinical staff member in Leiden and a visiting Professor in the Center for Thrombosis and Hemostasis in Mainz (Germany) allows Dr Klok to successfully participate in and lead large international trials and translational research projects. In addition to research, Dr Klok is active in teaching and supervises both Masters and PhD students. Dr Klok was nominated for a 2019 YIA following an ISTH2019 presentation.

Michelle Lavin (►Fig. 6) was awarded her medical degree in 2005 from the National University of Ireland, Galway. She completed specialist hematology training and a fellowship in coagulation hematology, receiving her Fellowship of the College of Pathologists (FRCPath) in 2013. Her PhD, awarded in 2017 from Trinity College Dublin, focused on clinical outcomes and biological basis of low VWF. Her current work explores the phenotypic variability and clinical impact of bleeding disorders as a Clinical Research Fellow in the Irish Centre for Vascular Biology, RCSI. Dr Lavin is dedicated to improving awareness and optimizing care for people with bleeding disorders. Dr Lavin was also nominated for a 2019 YIA following an ISTH2019 presentation.

Deeksha Khialani (►Fig. 7) is another PhD student, but located at the Department of Clinical Epidemiology at Leiden University Medical Center (LUMC), Netherlands. She has a

Table 1 Listing of relevant editorials published in STH as related to the initiation of the Eberhard F. Mammen awards, as well as previous award announcements

1. Favaloro EJ. Welcome to a special issue of seminars in thrombosis and hemostasis—the closing issue for 2008. <i>Semin Thromb Hemost</i> 2008;34:693–696
2. Favaloro EJ. A tribute to Eberhard F. Mammen, MD (1930–2008). <i>Semin Thromb Hemost</i> 2008;34:703–708
3. Favaloro EJ. Welcome to the first issue of seminars in thrombosis and hemostasis for 2009. <i>Semin Thromb Hemost</i> 2009;35:1–2
4. Favaloro EJ. Winners of the inaugural Eberhard F. Mammen award for most popular article. <i>Semin Thromb Hemost</i> 2009;35:587–590
5. Favaloro EJ. 2009 Eberhard F. Mammen Young Investigator Award Winners. <i>Semin Thromb Hemost</i> 2010;36:469–470
6. Favaloro EJ. Winners of the 2010 Eberhard F. Mammen award for most popular article during 2008–2009. <i>Semin Thromb Hemost</i> 2010;36(7):685–692
7. Favaloro EJ. 2011 Eberhard F. Mammen award announcements. <i>Semin Thromb Hemost</i> 2011;37(5):431–439
8. Favaloro EJ. 2012 Eberhard F. Mammen award announcements. <i>Semin Thromb Hemost</i> 2012;38:425–432
9. Favaloro EJ. 2013 Eberhard F. Mammen award announcements. <i>Semin Thromb Hemost</i> 2013;39:567–574
10. Favaloro EJ. 2014 Eberhard F. Mammen award announcements: part I—most popular articles. <i>Semin Thromb Hemost</i> 2014;40(4):407–412
11. Favaloro EJ. 2014 Eberhard F. Mammen award announcements: part II—Young Investigator Awards. <i>Semin Thromb Hemost</i> 2014;40(7):718–723
12. Favaloro EJ. 2015 Eberhard F. Mammen award announcements: part I—most popular articles. <i>Semin Thromb Hemost</i> 2015;41(7):673–679
13. Favaloro EJ. 2015 Eberhard F. Mammen award announcements: part II—Young Investigator Awards. <i>Semin Thromb Hemost</i> 2015;41(8):809–815
14. Favaloro EJ. 2016 Eberhard F. Mammen award announcements: part I—most popular articles. <i>Semin Thromb Hemost</i> 2016;42(4):325–330
15. Favaloro EJ. 2016 Eberhard F. Mammen award announcements: part II—Young Investigator Awards. <i>Semin Thromb Hemost</i> 2017;43(3):235–241
16. Favaloro EJ. 2017 Eberhard F. Mammen award announcements: part I—most popular articles. <i>Semin Thromb Hemost</i> 2017;43(4):357–363
17. Favaloro EJ. 2017 Eberhard F. Mammen award announcements: part II—Young Investigator Awards. <i>Semin Thromb Hemost</i> 2018;44(2):81–88
18. Favaloro EJ. 2018 Eberhard F. Mammen award announcements: part I—most popular articles. <i>Semin Thromb Hemost</i> 2018;44(3):185–192
19. Favaloro EJ. 2018 Eberhard F. Mammen award announcements: part II—Young Investigator Awards. <i>Semin Thromb Hemost</i> 2019;45(2):123–129
20. Favaloro EJ. 2019 Eberhard F. Mammen award announcements: part I—most popular articles. <i>Semin Thromb Hemost</i> 2019;45(3):215–224

Master's degree in Biomedical Sciences, with a special interest in Biostatistics. Her current research centers on “Big Data Epidemiology,” where she uses large amounts of mostly pharmacy data to answer research questions regarding the use of contraceptives and risk of VTE. Worldwide, millions of women use contraceptives. Her aim is to provide these women and their carers with the most up-to-date scientific knowledge regarding the safest form of contraceptive. Future studies are planned to also assess the association between contraceptives and risk of other diseases. Deeksha was also nominated for a 2019 YIA following an ISTH2019 presentation.

All award winners were elated to hear that they had been selected to receive an Eberhard F. Mammen Young Investigator Award, and provided the following additional commentary:

“It is my pleasure and privilege to have been nominated and selected for the prestigious Eberhard F. Mammen

Young Investigator Award. I truly appreciate the acknowledgment that this award has conveyed to many years of teamwork in the fascinating field of epigenetics. I would also like to thank the Editor in Chief of *Seminars in Thrombosis and Hemostasis*, Dr Favaloro, for bringing me this wonderful news, as well as my supervisors and colleagues for their support and collaboration, and for having so strongly supported and fostered my interest and enthusiasm in thrombosis and hemostasis research.”

– Elisa Danese (► Fig. 2)

“I am honored to have been nominated for and awarded an Eberhard F. Mammen Young Investigator Award. I would like to thank the editorial team of *Seminars in Thrombosis and Hemostasis* for this accolade. My research would not have been possible without the unwavering

Table 2 Latest (2019) Eberhard F. Mammen Young Investigator Award winners

Awardee	Current affiliation(s)	Presentation(s) awarded	Proposed submission to STH
Elisa Danese, PharmD, PhD	Department of Neurological, Biomedical and Movement Sciences, University of Verona, and Clinical Biochemistry Section, Hospital G.B. Rossi, Verona, Italy	ISTH2019. Presentation: epigenetics in hemostasis.	The role of epigenetics in the regulation of hemostatic balance.
Soracha Ward, BSc (Hons) (PhD candidate)	Trinity College, and Irish Centre for Vascular Biology, Royal College of Surgeons in Ireland, Dublin, Ireland	2018 American Society of Haematology Conference (San Francisco). Presentation: defining the molecular mechanisms through which the macrophage galactose lectin (MGL) receptor regulates von Willebrand factor clearance.	Lectin receptors—key modulators of VWF and FVIII biology.
Jonathan Douxflis, M Pharm Sc, PhD	University of Namur, CEO & Founder of QUALiblood, Belgium	ISTH2019. Presentation: a new algorithm based on thrombin generation to assess hormone-related prothrombotic changes. 11th ECAT meeting—Leiden (Netherlands; 2018) presentation: interference of DOACs on coagulation tests.	Venous thromboembolism and oral contraceptives: focus on testing that may enable prediction and assessment of the risk.
Erik Klok, MD PhD	Internist, Vascular Medicine specialist, Dept. of Medicine, Thrombosis and Hemostasis, Leiden University Medical Center	ISTH2019. Presentation: evaluation of the predictive value of the bleeding prediction score “VTE-BLEED” for recurrent venous thromboembolism.	Early diagnosis of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: state of the art and implications for daily practice.
Michelle Lavin, MD PhD	Irish Centre for Vascular Biology, Department of Molecular & Cellular Therapeutics, RCSI, Dublin, Ireland	ISTH2019. Presentation: VWD and pregnancy—results of an International Survey.	Areas of clinical uncertainty in the management of pregnancy for women with von Willebrand disease.
Deeksha Khialani, M BioMed Sc (PhD candidate)	Department of Clinical Epidemiology at Leiden University Medical Center (LUMC), Netherlands	ISTH2019. Presentation: thrombosis risk after switching oral contraceptive type.	Hormonal contraceptives and the risk of venous thrombosis.

Abbreviations: DOACs, direct oral anticoagulants; ISTH2019, International Society on Thrombosis and Haemostasis (ISTH) held in Melbourne, Australia, in July 2019; STH, Seminars in Thrombosis & Hemostasis; VTE, venous thromboembolism; VWD, von Willebrand disease; VWF, von Willebrand factor.

support of my colleagues in the Irish Centre of Vascular Biology, in particular my supervisor Professor James O'Donnell.”

– Soracha Ward (► Fig. 3)

“I am honored to have been awarded an Eberhard F. Mammen Young Investigator Award. I greatly appreciate the recognition of the voting committee for my research and current projects. This is a great achievement which would not have been possible without the support of my entire team and the wonderful mentorship that I have been afforded to date. In particular, Professor Jean-Michel Dogné and Professor François Mullier have been exceptional mentors and supervisors. I would also like to thank Robert C. Gosselin, Professors ten Cate, Verhamme, Ageno, and Samama for our numerous collaborations and sharing on hemostasis issues. This award acknowledges a team

effort and the hard work that has been put into these projects.”

– Jonathan Douxflis (► Fig. 4)

“I am honored to have received an Eberhard F. Mammen Young Investigator Award. I very much appreciate the recognition for my research. This award acknowledges a team effort by many. It is a pleasure to accept the award on their behalf, an award that will thrive our future research efforts.”

– Erik Klok (► Fig. 5)

“As the first Irish clinician to be awarded an Eberhard F. Mammen Young Investigator Award, I am honored to receive this prestigious prize for my work on postpartum hemorrhage (PPH) in women with von Willebrand disease (VWD). Our research group in the Irish Centre for Vascular Biology at RCSI continues to work to enhance care for

Table 3 Eberhard F. Mammen Young Investigator Award winners from previous years

Awardee	Year awarded	Publication arising
Willem M. Lijfering	2009	Lijfering WM, Flinterman LE, Vandenbroucke JP, Rosendaal FR, Cannegieter SC. Relationship between venous and arterial thrombosis: a review of the literature from a causal perspective. <i>Semin Thromb Hemost</i> 2011;37(8):885–896
Salley Pels	2009	Pels SG. Current therapies in primary immune thrombocytopenia. <i>Semin Thromb Hemost</i> 2011;37(6):621–630
Adam Cuker	2010	Cuker A. Current and emerging therapeutics for heparin-induced thrombocytopenia. <i>Semin Thromb Hemost</i> 2012;38(1):31–37
Giridhara Rao Jayandharan	2010	Jayandharan GR, Srivastava A, Srivastava A. Role of molecular genetics in hemophilia: from diagnosis to therapy. <i>Semin Thromb Hemost</i> 2012;38(1):64–78
Timea Szanto	2010	Szántó T, Joutsu-Korhonen L, Deckmyn H, Lassila R. New insights into von Willebrand disease and platelet function. <i>Semin Thromb Hemost</i> 2012;38(1):55–63
Birgitta Salmela	2010	Salmela B, Joutsu-Korhonen L, Armstrong E, Lassila R. Active online assessment of patients using new oral anticoagulants: bleeding risk, compliance, and coagulation analysis. <i>Semin Thromb Hemost</i> 2012;38(1):23–30
Pia Riittaa-Maria Siljander	2010	Aatonen M, Grönholm M, Siljander PR. Platelet-derived microvesicles: multitasking participants in intercellular communication. <i>Semin Thromb Hemost</i> 2012;38(1):102–113
Romarc Lacroix	2011	Lacroix R, Dignat-George F. Microparticles: new protagonists in pericellular and intravascular proteolysis. <i>Semin Thromb Hemost</i> 2013;39(1):33–39
Brad McEwen	2011	McEwen BJ, Morel-Kopp MC, Chen W, Tofler GH, Ward CM. Effects of omega-3 polyunsaturated fatty acids on platelet function in healthy subjects and subjects with cardiovascular disease. <i>Semin Thromb Hemost</i> 2013;39(1):25–32
Neil A. Goldenberg	2011	Bernard TJ, Armstrong-Wells J, Goldenberg NA. The institution-based prospective inception cohort study: design, implementation, and quality assurance in pediatric thrombosis and stroke research. <i>Semin Thromb Hemost</i> 2013;39(1):10–14
Vivien Chen	2011	Chen VM. Tissue factor de-encryption, thrombus formation, and thiol-disulfide exchange. <i>Semin Thromb Hemost</i> 2013;39(1):40–47
Joseph E. Italiano, Jr.	2011	Italiano JE Jr. Unraveling mechanisms that control platelet production. <i>Semin Thromb Hemost</i> 2013;39(1):15–24
Vivian Xiaoyan Du	2012/2013	Du VX, Huskens D, Maas C, Al Dieri R, de Groot PG, de Laat B. New insights into the role of erythrocytes in thrombus formation. <i>Semin Thromb Hemost</i> 2014;40(1):72–80
Andrew Yee	2012/2013	Yee A, Kretz CA. Von Willebrand factor: form for function. <i>Semin Thromb Hemost</i> 2014;40(1):17–27
Sarah O'Brien	2012/2013	O'Brien SH. Contraception-related venous thromboembolism in adolescents. <i>Semin Thromb Hemost</i> 2014;40(1):66–71
Veronica Flood	2012/2013	Flood VH. Perils, problems, and progress in laboratory diagnosis of von Willebrand disease. <i>Semin Thromb Hemost</i> 2014;40(1):41–48
Julie Tange	2012/2013	Tange JI, Grill D, Koch CD, et al. Local verification and assignment of mean normal prothrombin time and international sensitivity index values across various instruments: recent experience and outcome from North America. <i>Semin Thromb Hemost</i> 2014;40(1):115–120
Kent Chapman	2012/2013	Chapman K, Yuen S. Therapy for thrombotic thrombocytopenia purpura: past, present, and future. <i>Semin Thromb Hemost</i> 2014;40(1):34–40
Andreas Tiede	2014	Tiede A, Werwitzke S, Scharf RE. Laboratory diagnosis of acquired hemophilia a: limitations, consequences, and challenges. <i>Semin Thromb Hemost</i> 2014;40(7):803–811
Wendy Lim	2014	Lim W. Thrombotic risk in the antiphospholipid syndrome. <i>Semin Thromb Hemost</i> 2014;40(7):741–746
Susana Nobre Fernandes	2014	Fernandes S, Carvalho M, Lopes M, Araújo F. Impact of an individualized prophylaxis approach on young adults with severe hemophilia. <i>Semin Thromb Hemost</i> 2014;40(7):785–789
Maria Elisa Mancuso	2014	Mancuso ME, Fasulo MR. Thrombin generation assay as a laboratory monitoring tool during by-passing therapy in patients with hemophilia and inhibitors. <i>Semin Thromb Hemost</i> 2016;42(1):30–35
Coen Maas	2014	Tersteeg C, Fijnheer R, Deforche L, et al. Keeping von Willebrand factor under control: alternatives for ADAMTS13. <i>Semin Thromb Hemost</i> . 2016;42(1):9–17
Riten Kumar	2014	Kumar R, Dunn A, Carcao M. Changing paradigm of hemophilia management: extended half-life factor concentrates and gene therapy. <i>Semin Thromb Hemost</i> 2016;42(1):18–29

(Continued)

Table 3 (Continued)

Awardee	Year awarded	Publication arising
Juraj Sokol	2015	Sokol J, Skerenova M, Jedinakova Z, et al. Progress in the understanding of sticky platelet syndrome. <i>Semin Thromb Hemost</i> 2017;43(1):8–13
Ljubica Jovanović	2015	Jovanovic L, Antonijevic N, Novakovic T, et al. Practical aspects of monitoring of antiplatelet therapy. <i>Semin Thromb Hemost</i> 2017;43(1):14–23
Lucia Stanciakova	2015	Stanciakova L, Dobrotova M, Jedinakova Z, et al. Monitoring of hemostasis and management of anticoagulant thromboprophylaxis in pregnant women with increased risk of fetal loss. <i>Semin Thromb Hemost</i> 2016;42(6):612–621
Tina Biss	2015	Biss TT. Venous thromboembolism in children: is it preventable? <i>Semin Thromb Hemost</i> 2016;42(6):603–611
Tobias Fuchs	2015	Jiménez-Alcázar M, Kim N, Fuchs TA. Circulating extracellular DNA: cause or consequence of thrombosis? <i>Semin Thromb Hemost</i> 2017;43(6):553–561
Jonathan M. Coutinho	2015	Silvis SM, Middeldorp S, Zuurbier SM, Cannegieter SC, Coutinho JM. Risk factors for cerebral venous thrombosis. <i>Semin Thromb Hemost</i> 2016;42(6):622–631
Soundarya Selvam	2016	Selvam S, James P. Angiodysplasia in von Willebrand disease: understanding the clinical and basic science. <i>Semin Thromb Hemost</i> 2017;43(6):572–580
Vincent Muczynski	2016	Muczynski V, Christophe OD, Denis CV, Lenting PJ. Emerging therapeutic strategies in the treatment of hemophilia A. <i>Semin Thromb Hemost</i> 2017;43(6):581–590
Karen Schreiber	2016	Schreiber K, Breen K, Cohen H, et al. HYdroxychloroquine to improve pregnancy outcome in women with Antiphospholipid antibodies (HYPATIA) protocol: a multinational randomized controlled trial of hydroxychloroquine versus placebo in addition to standard treatment in pregnant women with antiphospholipid syndrome or antibodies. <i>Semin Thromb Hemost</i> 2017;43(6):562–571
Jasmine Wee Ting Tay	2016	Tay J, Tiao J, Hughes Q, Jorritsma J, Gilmore G, Baker R. Circulating MicroRNA as thrombosis sentinels: caveats and considerations. <i>Semin Thromb Hemost</i> 2018;44(3):206–215
Adi J. Klil-Drori	2016	Klil-Drori AJ, Tagalakis V. Direct oral anticoagulants in end-stage renal disease. <i>Semin Thromb Hemost</i> 2018;44(4):353–363
Lindsey A. George	2016	Submission pending.
Ivar van Asten	2017	van Asten I, Schutgens REG, Urbanus RT. Toward flow cytometry based platelet function diagnostics. <i>Semin Thromb Hemost</i> 2018;44(3):197–205
Laura Franco	2017	Submission pending.
Elodie Laridan	2017	Laridan E, Martinod K, De Meyer SF. Neutrophil extracellular traps in arterial and venous thrombosis. <i>Semin Thromb Hemost</i> 2019;45(1):86–93
Leonardo Pasalic	2017	Blennerhassett R, Curnow J, Pasalic L. Immune-mediated thrombotic thrombocytopenic purpura: a narrative review of diagnosis and treatment in adults. <i>Semin Thromb Hemost</i> 2020. In press
Yvonne Brennan	2017	Brennan Y, Favaloro EJ, Curnow J. To maintain or cease nonvitamin K antagonist oral anticoagulants prior to minimal bleeding risk procedures: a review of evidence and recommendations. <i>Semin Thromb Hemost</i> 2019;45(2):171–179
Georgia McCaughan	2017	Submission pending.
Mark Schreuder, MSc	2018	Schreuder M, Reitsma PH, Bos MHA. Reversal agents for the direct factor Xa inhibitors: biochemical mechanisms of current and newly emerging therapies. <i>Semin Thromb Hemost</i> 2020. In press
James McFadyen MBBS FRACP PhD	2018	Stevens H, McFadyen JD. Platelets as central actors in thrombosis-reprising an old role and defining a new character. <i>Semin Thromb Hemost</i> 2019;45(8):802–809
David Rabbolini BSc MBBCh (Witw.), FRACP FRCPA PhD	2018	Submission pending.
Janka Zolkova, MSc	2018	Zolkova J, Sokol J, Simurda T, et al. Genetic background of von Willebrand disease: history, current state and future perspectives. <i>Semin Thromb Hemost</i> 2020. In press
Tomáš Bolek MD	2018	Bolek T, Samoř M, Škorňová I, et al. Proton pump inhibitors and dabigatran therapy: impact on gastric bleeding and dabigatran plasma levels. <i>Semin Thromb Hemost</i> 2019;45(8):846–850
Fraser McCrae BSc (Hons)	2018	Submission pending.



Fig. 2 Young Investigator Award winner Elisa Danese.



Fig. 3 Young Investigator Award winner Soracha Ward.



Fig. 4 Young Investigator Award winner Jonathan Douxflis.




Fig. 5 Young Investigator Award winner Erik Klok.

people with bleeding disorders. Improved PPH prevention strategies for women with VWD is a prior focus of the VWF and Women's Health Scientific Subcommittees of the ISTH, with whom I collaborated on this project. I would like to thank all of those involved in this project to date and look forward to work in future toward improving our knowledge and evidence base in this field."

- Michelle Lavin (►**Fig. 6**)

"I am extremely honored and humbled for being awarded an Eberhard F. Mammen Young Investigator Award. This award acknowledges team effort and the hard work that has been put into this project. Therefore, I would like to thank my supervisors Dr Astrid van Hylckama Vlieg and Professor Frits Rosendaal for their wonderful support and



Fig. 6 Young Investigator Award winner Michelle Lavin.

mentorship. In addition, this project would not have been possible without Ms Esther de Rooij, a dedicated master student and Professor Saskia le Cessie, an incredible statistician at our Department of Clinical Epidemiology."

- Deeksha Khialani (►Fig. 7)

In keeping with previous editorials, I have again reviewed the Young Investigator awardees from previous years as well



Fig. 7 Young Investigator Award winner Deeksha Khialani.

as the outcome of their subsequent submissions to STH, as summarized in ►Table 3. The most recent contributions are listed in the reference list.^{3–15} I previously mentioned my personal gratification that most of the papers from earlier years have subsequently appeared in several annual top 100 listings. Of further interest, some of these papers or the young investigators themselves have subsequently won one of the most popular awards. It is also motivating to observe that several of the Young Investigator awardees were co-authors on other contributions to STH that were also listed in these most popular listings.

I look forward to seeing the careers of the current and past YIA winners to continue to develop. The above noted findings also infer that very high bars have been established for future Young Investigator awardees, and I wish all awardees best of luck to exceed the precedence set by earlier award winners.

Conflicts of Interest

None declared.

References

- 1 Favaloro EJ. 2019 Eberhard F. Mammen award announcements: part I-most popular articles. *Semin Thromb Hemost* 2019;45(03): 215–224
- 2 Ward SE, O'Sullivan JM, Drakeford C, et al. A novel role for the macrophage galactose-type lectin receptor in mediating von Willebrand factor clearance. *Blood* 2018;131(08):911–916
- 3 Selvam S, James P. Angiodysplasia in von Willebrand disease: understanding the clinical and basic science. *Semin Thromb Hemost* 2017;43(06):572–580
- 4 Muczynski V, Christophe OD, Denis CV, Lenting PJ. Emerging therapeutic strategies in the treatment of hemophilia A. *Semin Thromb Hemost* 2017;43(06):581–590
- 5 Schreiber K, Breen K, Cohen H, et al. Hydroxychloroquine to Improve Pregnancy Outcome in Women with AntiPhospholipid Antibodies (HYPATIA) Protocol: a multinational randomized controlled trial of hydroxychloroquine versus placebo in addition to standard treatment in pregnant women with antiphospholipid syndrome or antibodies. *Semin Thromb Hemost* 2017;43(06): 562–571
- 6 Tay J, Tiao J, Hughes Q, Jorritsma J, Gilmore G, Baker R. Circulating MicroRNA as thrombosis sentinels: caveats and considerations. *Semin Thromb Hemost* 2018;44(03):206–215
- 7 Klil-Drori AJ, Tagalakis V. Direct oral anticoagulants in end-stage renal disease. *Semin Thromb Hemost* 2018;44(04):353–363
- 8 van Asten I, Schutgens REG, Urbanus RT. Toward flow cytometry based platelet function diagnostics. *Semin Thromb Hemost* 2018; 44(03):197–205
- 9 Laridan E, Martinod K, De Meyer SF. Neutrophil extracellular traps in arterial and venous thrombosis. *Semin Thromb Hemost* 2019; 45(01):86–93
- 10 Blennerhassett R, Curnow J, Pasalic L. Immune-mediated thrombotic thrombocytopenic purpura: a narrative review of diagnosis and treatment in adults. *Semin Thromb Hemost* 2020. In press
- 11 Brennan Y, Favaloro EJ, Curnow J. To maintain or cease non-vitamin K antagonist oral anticoagulants prior to minimal bleeding risk procedures: a review of evidence and recommendations. *Semin Thromb Hemost* 2019;45(02):171–179
- 12 Schreuder M, Reitsma PH, Bos MHA. Reversal agents for the direct factor Xa inhibitors: biochemical mechanisms of current and newly emerging therapies. *Semin Thromb Hemost* 2020. In press

- 13 Stevens H, McFadyen JD. Platelets as central actors in thrombosis—reprising an old role and defining a new character. *Semin Thromb Hemost* 2019;45(08):802–809
- 14 Zolkova J, Sokol J, Simurda T, et al. Genetic background of von Willebrand disease: history, current state and future perspectives. *Semin Thromb Hemost* 2020. DOI: 10.1055/s-0039-3402430 (epub ahead of print)
- 15 Bolek T, Samoř M, Škorňová I, et al. Proton pump inhibitors and dabigatran therapy: impact on gastric bleeding and dabigatran plasma levels. *Semin Thromb Hemost* 2019;45(08):846–850